-ph. Eur.- Monograph Tablets -0478- ((install)) | European Pharmacopoeia

┌─────────────────────────────────────────────────────────────┐ │ Ph. Eur. Monograph 0478 │ └──────────────────────────────┬──────────────────────────────┘ │ ┌───────────────────────┼───────────────────────┐ ▼ ▼ ▼ Effervescent Dispersible Gastro-resistant ┌──────────────────────┐ ┌───────────────────┐ ┌───────────────────┐ │ Disintegrates

Manufacturers must adhere to specific "Production" and "Test" sections to satisfy regulatory bodies like the European Directorate for the Quality of Medicines & HealthCare (EDQM) . 1. Disintegration Testing (General Chapter 2.9.1)

The active substance(s) must be identified using the tests prescribed in the specific monograph for that substance (e.g., spectroscopy, chromatography). European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Pharmaceutical manufacturing operates on a global scale, making regulatory alignment highly desirable. The EDQM actively participates in the alongside the United States Pharmacopeia (USP) and the Japanese Pharmacopoeia (JP).

In the landscape of global pharmaceutical regulation, quality standards serve as the silent guardians of public health. Among the most authoritative of these standards is the European Pharmacopoeia (Ph. Eur.), a legally binding benchmark for all medicines marketed within European Union member states. Within this collection, , occupies a foundational role. Unlike monographs for specific active substances (e.g., Paracetamol or Atorvastatin), the Tablets monograph establishes the general quality requirements for one of the most common and ancient pharmaceutical dosage forms. This essay examines the scope, key tests, and regulatory significance of Ph. Eur. Monograph 0478, arguing that it provides a universal quality framework that ensures the safety, efficacy, and reliability of oral solid dosage forms across Europe and beyond. The EDQM actively participates in the alongside the

A monograph in the Ph. Eur. is a detailed description of a specific medicinal product, including its composition, manufacturing process, and quality control tests. Monographs provide a standardized description of a product, which ensures that all products that meet the monograph requirements are of equivalent quality.

To stay aligned with technological and regulatory advances, the European Pharmacopoeia Commission continuously refines its monographs. A major revision of Monograph 0478 was published in , becoming effective on January 1, 2018 . Key updates from this revision included: split them by hand

: Analysts select 30 tablets at random, split them by hand, and collect one-half from each tablet.

Would you like a side-by-side comparison with the USP or JP tablet monographs as well?